title: What do we know about the α/β for prostate cancer?
abstract: Since last decade, the debate on the parameter which reflects prostate cancer sensitivity to fractionation in a radiotherapy treatment, the α/β, has become extensive. Unlike most tumors, the low labeling indices (LI) and large potential doubling time that characterize the prostate tumor led some authors to consider that it may behave as a late responding tissue. So far, the existing studies with regard to this subject point to a low value of α/β, around 2.7 Gy, which may be considered as a therapeutic gain in relation to surrounding normal tissues by using fewer and larger fractions. The aim of this paper is to review several estimates that have been made in the last few years regarding the prostate cancer α/β both from clinical and experimental data, as well as the set of factors that have potentially influenced these evaluations.
authors: Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo Mártires da Pátria, 130, 1169-056 Lisbon, Portugal.
authors: S M
authors: SM
authors: Oliveira
authors: N J
authors: NJ
authors: Teixeira
authors: L
authors: L
authors: Fernandes
mesh_terms: D015687:Cell Hypoxia / Q000528:radiation effects; D045744:Cell Line, Tumor; D019583:Dose Fractionation, Radiation; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D016032:Randomized Controlled Trials as Topic; D012062:Relative Biological Effectiveness